In a previous report we have shown in ER+ breast cancer cell lines that the first generation proteasome inhibitor (PI) bortezomib decreased expression of ERα and HER2 and inhibited signalling pathways responsible for induction of endocrine resistance [32]. This evidence concerns the gene ERBB2 and breast carcinoma.